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Summary
Background; Anemia is a common side effect of anticancer
chemotherapy. Blood transfusion, previously the only available
treatment for chemotherapy-induced anemia, may result in
some clinical or subclinical adverse effects in the recipients.
Recombinant human erythropoietin (rhEPO) provides a
new treatment modality for chemotherapy-induced anemia.
Patients and methods: To evaluate the effect of rhEPO on
the need for blood transfusions and on hemoglobin (Hb)
concentrations, 227 patients with solid tumors and chemo-
therapy-induced anemia were enrolled in a randomized, con-
trolled, clinical trial. Of 189 patients evaluable for efficacy, 101
received 5000 IU rhEPO daily s.c, while 88 patients received
no treatment during the 12-week controlled phase of the study.
Results: The results demonstrate a statistically significant
reduction in the need for blood transfusions (28% vs. 42%, P =
0.028) and in the mean volume of packed red blood cells trans-
fused (152 ml vs. 190 ml, P = 0.044) in patients treated with
rhEPO compared to untreated controls. This effect was even
more pronounced in patients receiving platinum-based che-
motherapy (26% vs. 45%, P = 0.038).
During the controlled treatment phase, the median Hb
values increased in the rhEPO patients while remaining un-
changed in the control group. The response was seen in all
tumor types.
Conclusions: RhEPO administration at a dose of 5000 IU
daily s.c. increases hemoglobin levels and reduces transfusion
requirements in chemotherapy-induced anemia, especially dur-
ing platinum-based chemotherapy.
Key words: anemia, chemotherapy, malignancy, recombinant
human erythropoietin
Introduction
In many cancer patients, anemia is a consequence of the
malignant disease process itself. Cancer-related anemia
is associated with excessive release of cytokines such as
interleukin-1, tumor necrosis factor and interferons
[1]. These immunomodulatory peptides interfere with
endogenous erythropoietin (EPO) production and in-
hibit erythroid bone marrow production [2].
Myelosuppressive chemotherapy can exacerbate the
development and progression of anemia in patients with
malignant disease. Depending on the cytotoxic agents
used and their cumulative doses, the incidence of trans-
fusion-dependent anemia induced by platinum-contain-
ing chemotherapy ranges from 9% to 40% [3].
Anemia related to platinum-containing chemotherapy
may be associated with two different mechanisms. Cis-
platin impairs erythropoiesis by a direct toxic effect on
renal erythropoietin-producing cells, resulting in inap-
propriate EPO levels relative to the degree of anemia [4,
5]. In addition, platinum-based chemotherapy suppresses
erythroid progenitor cells in the bone marrow, an effect
that is more prominent with carboplatin than with
cisplatin [6].
The clinical symptoms in patients with malignant
diseases and anemia range from fatigue and lethargy to
dyspnea and cardiovascular effects as well as a reduced
capacity for physical activity. Chemotherapy, radiother-
apy or surgical treatment may be less well tolerated in
the presence of anemia.
Many patients with chemotherapy-induced anemia
require regular transfusions. Complications of tranfu-
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sions, such as transmitted infections and immune or
intolerance reactions, are rare, but they can have serious
consequences [7]. Although in most European countries
blood transfusions can be given on an outpatient basis,
for many patients the application is associated with
hospitalization.
Recombinant human erythropoietin (rhEPO) has
been accepted as the standard treatment for anemia of
chronic renal failure [8, 9], and phase I-II clinical studies
have shown that rhEPO can ameliorate chronic and
chemotherapy-induced anemia and reduce the need for
transfusions in patients with various malignant diseases
[6,10-15].
The aim of this study was to consolidate data on the
efficacy of rhEPO in patients with solid tumors and to
identify subgroups of patients that exhibit the most
pronounced benefit in order to optimize the use of this
therapy in cancer patient populations.
Patients and methods
Patients
This study was approved by the local Ethics Committees, and carried
out in accordance with the Helsinki Declaration All patients enrolled
gave their informed consent.
Patients were eligible for the study if the following inclusion criteria
were fulfilled: 1) adult patients (age > 18 years) undergoing chemo-
therapy for solid malignant tumors with histologically and/or cytolog-
ically proven diagnoses; 2) anemia with hemoglobin (Hb) concentra-
tion =S 11 g/dl before first rhEPO administration; 3) Hb concentration
< 13.5 g/dl before first rhEPO administration, and drop in Hb concen-
tration by at least 1.5 g/dl during the preceding chemotherapy cycle; 4)
and had had at least one blood transfusion during the preceding
chemotherapy cycle.
The following major exclusion criteria were adopted: I) significant
organ dysfunction not secondary to malignancy: 2) therapy-resistant
hypertension; 3) thrombocytosis >500,000/ul; 4) iron deficiency or
other remediable causes of anemia (e.g., renal insufficiency); 5) epi-
lepsy; 6) acute infection; 7) acute or chronic bleeding.
Study design
The study was implemented as an open, randomized, controlled,
parallel-group study (controlled treatment phased out over 12 weeks).
After the controlled treatment phase all patients received treatment
with rhEPO. within an uncontrolled treatment phase over 12 weeks
(results not included). RhEPO was administered at a dose of 5000 IU
daily s.c, corresponding to approx. 450 IU/kg and week. The rhEPO
was provided as epoetin beta by Boehringer Mannheim GmbH
(Mannheim, Germany).
The primary variable of efficacy was the volume of packed red
blood cells (PRBC) transfused during four-week intervals (i.e.. weeks
1-4, 5-8, and 9-12) in the controlled treatment phase. In addition, the
proportion of patients with transfusions and the transfusion-free time
were analyzed. A secondary variable was the proportion of patients
with response to treatment defined as a Hb increase > 2 g dl compared
with baseline in a four-week interval during the controlled treatment
phase, maintained without transfusions in that period or the previous
four weeks. The time required until the first response to treatment was
also analyzed.
Hematology was measured weekly, whereas biochemistry and iron
metabolism parameters were determined every four weeks.
The safety of the rh-EPO treatment was assessed using spontane-
ously reported adverse events and safety laboratory variables. Anti-
EPO antibodies were measured at baseline and at the end of the
controlled treatment phase Endogenous erythropoietin levels were
measured within three to seven days before the start of erythropoietin
administration. No further measurements were made during the con-
trolled treatment phase.
Statistical methods
Sample size was calculated for this trial to allow for 90% power to
detect a difference in the volume of PRBC transfused per four weeks
between the two treatment groups at a significance level of 5%. The
resulting planned sample size was to enroll 300 patients with an aim of
accruing 86 evaluable patients in each group completing the controlled
treatment phase.
Wilcoxon's rank-sum test was used to compare the two groups with
respect to the primary efficacy variable (transfusion volume required
per four weeks). The number and percentage of patients with trans-
fusion was calculated for the various four-week intervals (weeks 1-4,
5-8. and 9-12). The time to first transfusion and time to response were
analyzed by the Kaplan-Meier method and the log-rank test, whereby
a withdrawal due to death, adverse event, or non-response was consid-
ered non-response rather than censored. The influence of various
factors on transfusion need and time to response was also evaluated.
The following factors were considered: type of tumor, platinum-con-
taining versus non-platinum-containing chemotherapy, platelet counts
(<150 x 109/l vs. > 150 x 109/l), distant metastasis (yes, no, not
assessable), previous blood transfusions (yes vs. no), gender, serum
EPO level at baseline (=£50 mU/ml vs. >50mU/ml), ratio of observed
vs predicted serum EPO level at baseline (O/P ratio) according to
Beguin [15] (< 0.9 vs. > 0 9), transferrin saturation ($ 20% vs. > 20%),
and location of investigation (Germany, Italy, France, and other
countries).
Results
Study population
Two hundred twenty-seven patients were randomized to
treatment with rhEPO (n = 117) or to the control group
(n - 110). Two hundred eighteen patients (rhEPO: n =
114; control: n = 104) started with the controlled treat-
ment phase. Sixty-two patients in the control group and
75 patients in the rhEPO group completed the controlled
phase of the study. Tumor progression, discontinuation
of chemotherapy, and personal reasons were the most
numerous causes of patient withdrawal in both groups.
One hundred eighty-nine patients were evaluable for
efficacy (101 in the rhEPO group and 88 in the control
group), and 218 patients were evaluated for safety (114 in
the rhEPO group and 104 in the control group). Charac-
teristics of the patients included in the efficacy evalua-
tion are described in Table 1.
The most common cancer was ovarian (n — 50),
followed by breast and lung cancers. The prevalence of
distant metastasis was 43% in both treatment groups.
The proportion of patients with bone metastasis,
which may influence hematopoietic capacity, was simi-
lar within the group of rhEPO-treated and controlled
patients (11% vs. 10%).
Fifty-seven patients (65%) in the control group and
58 (57%) in the rhEPO group had received chemother-
apy during the four weeks prior to starting the con-
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Table 1. Patient characteristics and baseline laboratory values. Trans-
fusion requirement within four weeks prestudy (Percentage of patients
transfused, mean volume of packed red blood cells [PRBC]).
Control RhEPO
group group
(n = 88) (n = 101)
Patient characteristics
Sex
Male 26 (30%) 23 (23%)
Female 62 (70%) 78 (77%)
Gynecological cancer 32 (36%) 36 (36%)
Breast cancer 22 (25%) 25 (25%)
Lung cancer 10(11%) 9(9%)
Urinary tract cancer 10(11%) 10(10%)
Gastrointestinal cancer 6(7%) 12(12%)
Other 8 (9%) 9 (9%)
Age (years)
Median 56 53
Range 19-73 20-77
Weight (kg)
Median 62 61
Range 41-110 43-103
Baseline hematology (median values)
Hemoglobin (g/dl) 10.3 9.6
Hematocnt (%) 30.1 29.4
Reticulocytes (%o) 10.2 10.2
Platelets (109/l) 267 284
Leukocytes (109/l) 5.18 5.25
Neutrophils(109/1) 3.52 3.41
Transfusions within four weeks prestudy
Patients transfused (%) 21.6 22.8
Volume of PRBC (mean) 133 ml 166 ml
Baseline EPO concentration (n = 52) (n - 72)
Median serum-EPO (mU/ml) 27.7 26.0
O/P ratio for serum-EPO 0.74 0.69
O/P ratio 40.9 40(77%) 63(83%)
trolled treatment phase. Most of the patients were
treated with combination chemotherapy. During the
controlled treatment phase, more than half of the pa-
tients received platinum-based chemotherapy, 70 of
them including cisplatin and 36 carboplatin. The distri-
bution of increased doses of cisplatin or carboplatin at
the beginning of the controlled treatment phase was
balanced within the two treatment groups. Sixty-three
percent of the patients received cisplatin at a dose level
of > 75 mg/m2/cycle and 72% received carboplatin at a
dose level of > 250 mg/m2/cycle.
As shown by the decreased neutrophil count (7% in
both groups) there was an increased chemotherapy-in-
duced depression of hematopoiesis during the controlled
treatment phase as compared to baseline. Baseline hem-
atological parameters, endogenous EPO production and
prestudy transfusion requirement are summarized in
Table 1.
Efficacy of rhEPO treatment
During the controlled treatment phase, the need for
transfusions was reduced in patients treated with rhEPO
but increased in control patients (Figure 1). This effect
was most prominent in the second month of treatment
50
Percent of patients
40 -
30 -
20 -
10 -
OControl group
lEpoetin beta group 40.9
-4M 4/1 5/8 9/12
Pretreatment Weeks of controlled treatment phase
1/12 (total)
Figure 1. Percentage of patients with transfusions in the four-week
intervals during the controlled treatment phase.
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Figure
Kaplan
2. Time to response separated by treatment group using
-Meier estimation for the probability for response.
(12% in the rhEPO group vs. 28% in the control group).
The mean volume of PRBC transfused per four weeks
was significantly lower in the rhEPO group (152 ml) than
in the control group (190 ml, P = 0.044 in comparison to
control).
The estimated probability of transfusion need within
12 weeks was 42% for the untreated controls and 28%
for rhEPO-treated patients.
Response to treatment after 12 weeks of therapy was
shown in 38% of rhEPO-treated patients, whereas only
9% of the untreated patients fulfilled the criteria for
treatment response. The time to response according to
treatment group is shown in Figure 2.
Analysis of prognostic factors for response
The subgroup analysis of various factors that may influ-
ence the need for blood transfusion and the effect of
rhEPO treatment identified the type of chemotherapy
and the administered dose level as predictive factors for
the probability of response to rhEPO treatment. The
need for transfusions was significantly lower (P -
0.0376) in the rhEPO group than in the control group in
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Table 2. Number and percentage of patients with blood transfusions (BT) and response to rhEPO treatment in various subgroups during the
controlled treatment phase.
Patients subgroup Study arm Patients with Life table rate Patients with Life table rate
BT(%) forBT(%)a response (%) for response
Type of chemotherapy
Platinum-containing chemotherapy
Type of tumor
Platinum-containing chemotherapy
With platinum
Without platinum
Low dose
Increased dose
Ovarian cancer
Other tumors
Ovarian cancer
Other tumors
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
14/57(25)
22/51 (43)
12/44(27)
14/37(38)
5/28(18)
8/26(31)
7/27(26)
14/25 (56)
7/27 (26)
9/23 (39)
19/74(26)
27/65(41)
6/23(26)
8/19(42)
8/34(23)
14/32 (44)
26
45
31
39
18
31
30
59
28
39
28
42
27
42
25
45
23/57(40)
4/51(8)
12/44(27)
2/37(5)
11 /28(39)
2/26(8)
12/27(44)
2/25 (9)
9/27(33)
2/23(9)
26/74(35)
4/65 (6)
8/23(35)
2/19(10)
15/34(44)
2/32 (6)
50
9
33
6
41
8
58
9
47
10
41
7
63
12
48
7
a
 Life table rate for blood transfusions and response (Kaplan-Meier estimation) after 12 weeks of the controlled treatment phase. Median time to
response and median time to first blood transfusion could not be estimated because of the limited study duration.
patients treated with platinum-based chemotherapy. In
control patients receiving an increased dose of cisplatin
(^75 mg/m2/cycle) or carboplatin (^ 350 mg/m2/cycle),
the transfusion need was about twice as high as that in
patients receiving lower doses (Table 2).
Subgroup analysis of patients receiving platinum-
based chemotherapy was performed comparing patients
with ovarian cancer vs. the combined subgroup includ-
ing those with all other entities, due to the smaller
number in these subgroups. In both groups of patients,
rhEPO-treated patients demonstrated a need for trans-
fusions lower by the same magnitude as compared to
untreated controls. For the same subgroups a markedly
higher response rate was seen in rhEPO-treated patients
than in the control group (Table 2).
During the controlled treatment phase, the median
Hb values measured at regular visits, irrespective of
blood transfusions, increased gradually in rhEPO pa-
tients, whereas the median hemoglobin concentration in
the control group remained unchanged. Two weeks after
the beginning of rhEPO treatment the median hemoglo-
bin concentration increased by 0.15 g/dl over that of the
baseline value, whereas in the control group a decrease
of hemoglobin concentration (-0.34 g/dl) was observed.
This finding should be viewed against the background
of frequency and volumes of transfusions, which were
higher in the control group.
Analysis of endogenous EPO production demon-
strated no correlation between EPO deficiency and re-
sponse to rhEPO treatment for either an absolute EPO
deficiency or for a baseline O/P ratio < 0.9. The same
holds true for the subgroup of patients receiving plati-
num-based chemotherapy, where baseline EPO levels
and O/P ratio were not predictive of the need for blood
transfusions or treatment response. To obtain an ad-
equate sample size in patients with platinum-based che-
motherapy the cut-off point of the O/P ratio had to be
changed to 0.8 for this subgroup (Table 3). These results
have to be viewed against the background of the high
proportion of patients in whom baseline EPO levels
were not determined. Therefore, analysis of serum EPO
levels and O/P ratio as a predictive factor for response
to rhEPO treatment does not demonstrate reliable re-
sults, and has to be interpreted with caution.
Safety of rhEPO treatment
RhEPO was found to be safe and well tolerated both
systemically and locally. None of the adverse events
leading to death or withdrawal during the controlled
treatment phase (14 deaths and seven withdrawals in
104 controls and eight deaths and 17 withdrawals in 114
rhEPO patients) were classified as being causally related
to the study medication. Serious adverse events were
reported for 30 of the 114 patients (26%) in the rhEPO
group and 29 of the 104 control patients (28%). The
nature and incidence of adverse experiences were sim-
ilar in the two treatment groups.
Adverse events that were assessed as being possibly
related to rhEPO therapy and that occurred during the
controlled treatment phase included allergic reaction,
hypertension, injection site pain, and rash (one patient
each), as well as iron deficiency (four patients) and
thrombocytopenia (two patients). There was no evidence
of an effect of rhEPO therapy on blood pressure in
patients in this study.
In addition, there were no trends toward clinically
relevant changes in any of the safety laboratory variables
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Table 3. Number and percentage of patients with blood transfusions (BT) and response to rhEPO-treatment dependent on serum EPO levels at
baseline ($ 50 vs. > 50 mU/ml) and ratio of observed vs. predicted serum EPO level (O/P ratio $ 0.9 vs. > 0.9).
Serum EPO level at baseline (mUml)
O/P ratio
Platinum-containing chemotherapy
$50
>50
$0.9
>0.9
O/P ratio $0 8
O/P ratio >0.8
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
rhEPO
Control
Patients with
BT (%)
10/60(17)
7/36(19)
8/18(44)
6/16(38)
11/63(18)
9/40 (23)
6/13(46)
4/12(33)
7/31 (23)
7/22 (32)
4/11(36)
1/9 (11)
Life table rate
for BT (%)a
19
21
46
38
20
23
48
33
25
34
39
11
Patients with
response (%)
24/60(40)
1/36(3)
6/18(33)
2/16(13)
25/63(40)
1/40(3)
4/13(31)
2/12(17)
14/31 (45)
1/22(5)
4/11 (36)
2/9 (22)
Life table rate
for response
46
3
50
15
46
3
47
20
55
5
52
25
a
 Life table rates for blood transfusions and response to treatment (Kaplan-Meier estimation) after 12 weeks of the controlled treatment phase.
Median time to response and median time to first BT could not be estimated because of the limited study duration.
in either of the groups. No antibodies against rhEPO
developed during therapy in the study.
Discussion
The results of this open, randomized, controlled, paral-
lel group study demonstrate that treatment with 5000
IU/day rhEPO s.c. leads to a reduction in the need for
transfusions in patients with solid tumors during che-
motherapy. The effect was particularly pronounced in
patients receiving platinum-based chemotherapy. As
expected from the underlying pathophysiological mech-
anisms of platinum-based chemotherapy in the develop-
ment of anemia, there was no difference in rhEPO
efficacy between ovarian cancer and other tumor types
treated with platinum-containing chemotherapy. These
results suggest that the effect of rhEPO is independent of
solid tumor type with regard to its efficacy in preventing
platinum-induced anemia.
The results of our study confirm those of several
published studies in patients with various solid tumors
treated with rhEPO. Such studies have consistently dem-
onstrated that rhEPO treatment, independent of the
underlying tumor type, leads to a significant reduction
in the need for blood transfusions, and prevents a de-
crease in hemoglobin (thus preventing the development
of anemia) or induces a considerable increase in hemo-
globin [6,11, 16].
In addition, our data show that the transfusion need
is most pronounced in patients receiving increased doses
of platinum-containing chemotherapy, in these patients
rhEPO treatment may be particulary indicated.
Data from hemodialysis patients have shown that
iron deficiency is one of the important factors leading
to a reduction in the efficacy of rhEPO treatment [17]. At
the end of the controlled treatment phase of our study,
about half of the patients exhibited functional iron
deficiency (transferrin saturation < 20%). To ensure that
patients receive maximum benefit from rhEPO treat-
ment, sufficient iron supplementation may be necessary
[18,19].
Although several clinical trials have demonstrated
that rhEPO is an effective treatment in tumor- or che-
motherapy-induced anemia, only a portion of patients
respond to rhEPO therapy. As rhEPO treatment is
expensive, it is important to determine a reliable means
of predicting responders and nonresponders in these
non-renal applications [10, 12, 20]. In our study, the
relative EPO deficiency was not a predictive factor for
response. Abels et al. report that endogenous erythro-
poietin levels are only a predictive factor in cancer
patients without chemotherapeutic treatment. He found
no statistically significant relationship between endoge-
nous EPO concentration and response to rhEPO treat-
ment in patients whose chemotherapy contained plati-
num and those whose CT did not [21]. The reasons for
these findings are still unclear but may be related to the
observation of temporarily increased levels of erythro-
poietin after administration of cyclic chemotherapy [22].
About 60% of our patients had received chemotherapy
four weeks before the beginning of the controlled treat-
ment phase. This may explain the negative relationship
between endogenous EPO concentration and response
in our study. On the other hand, our results could be
biased by the high percentage of patients (31%) in whom
baseline serum levels were not determined.
The analysis of various factors likely to be predictive
of response (platelet counts, distant metastasis, previous
blood transfusions, gender, transferrin saturation, inves-
tigational site location) demonstrate in almost all of the
subgroups analyzed a marked reduction of blood trans-
fusions and a higher rate of response in the epoetin beta-
treated patients than in the control group. Due to the
smaller sample sizes within the subgroups the differences
between the treatment groups do not reach significant
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values. Therefore, the interpretation of these results is
not reliable.
In summary, the results of this randomized, controlled
study demonstrate that rhEPO provides an effective, safe
and well tolerated alternative treatment modality that can
significantly delay or abolish the need for blood trans-
fusions in patients with solid tumors and chemotherapy-
induced anemia. However, the use of rhEPO-treatment
is expensive. One week of rhEPO administration at a
dose level of 450 IU/kg costs approximately $400. In
contrast the estimated average direct costs of an allo-
genic unit of blood ranges from $150 to $422, represent-
ing the total costs of blood collection, disease testing,
processing and inventory management, and compatibil-
ity testing [23].
Evaluation of cost-effectiveness in rhEPO therapy
and blood transfusions has to be viewed against the
background of two different treatment strategies. Blood
transfusions are suitable for the immediate treatment of
chemotherapy-induced anemia, especially if very low
hemoglobin concentrations occur and the patient be-
comes symptomatic, but they provide only a short-term
treatment effect and many patients require recurrent
blood transfusions during chemotherapy. RhEPO ther-
apy is effective for prevention and correction of chemo-
therapy-induced anemia, and compared to blood trans-
fusions it can ensure continuous hemoglobin levels for a
long treatment period. Because of these two different
treatment strategies it is very difficult to evaluate the
cost-effectiveness of rhEPO therapy, but an ongoing
clinical trial was conducted to analyze the cost-effective-
ness of rhEPO compared to blood transfusions.
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